TMU Research Center of Cancer Translational Medicine

Contact Information
Tel: +886-2-6636 9060 ext. 7713

E-mail: jychang@nhri.edu.tw

1. Development of anticancer drugs
2. Study the mechanisms of anticancer drug resistance.

Research projects

1. A phase III study of postoperative adjuvant chemoradiotherapy for patients with stage III and IVb stomach cancer. (PI)
2. A phase II study of gemcitabine and vinorelbine in cisplatin-resistant nasopharyngeal carcinoma patients. (co-PI)
3. A phase I study of PI-88 in advanced malignancies. (co-PI)
4. A phase I and PK study of thalidomide in hepatocellular carcinoma. (co-PI)
5. A phase II study of weekly CPT-11 in recurrent NPC. (PI)
6. A phase II study of weekly oxaliplatin plus HDFL in patients with advanced gastric cancer (co-PI)
7. A phase II study of taxol, UFT and leucovorin in patients with advanced gastric cancer. (co-PI)
8. A phase I/II study of docetaxel, cisplatin and HDFL in patients with advanced gastric cancer. (PI)
9. A phase III study of thalidomide in patients with poor liver function hepatocellular carcinoma. (co-PI)
10. Phase I and PK studies of PEP02 in patients with advanced malignancies. (PI)
11. Phase I study of PEP02 with HDFL in patients with advanced malignancies. (co-PI)
12. Phase I and PK study of biweekly PEP02 in patients with advanced colorectal cancer (PI).
13. A phase II study of neoadjuvant bio-chemotherapy with cetuximab, paclitaxel, and cisplatin (CPC) followed by cetuximab-based concurrent bio-radiotherapy in high-risk locally advanced squamous cell carcinoma of the oral cavity (OSCC). (PI)

Basic studies

1. Study the distribution of somatostatin receptor in human cancer tissue.
2. Study the mechanism of CPT resistance in human nasopharyngeal cancer cells.
3. Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.
4. Synthesis and structure-activity relationships of new AHMA derivatives as topoisomerase-II mediated antitumor agents.
5. Study the indole derivatives as antitumor agents.
6. Study the mechanims of action of BPR0Y007, a novel anticancer agent.
7. Study the role of O⁶-MGMT in determining the cytotoxicty of topoisomerase I inhibitors.
8. Transcriptional inhibition of MGMT gene of topoisomerase I inhibitors.
9. Isolation the putative transporter responsible for resistance to topoisomerase I inhibitors in a vincristine-resistant cell line.
10. Study the mechanism of action of a potential antitumor agent isolated from a herb medicine.

more

1. Study the interaction of arsenic trioxide with antitumor agents.
2. Study the interaction of new topoisomerase I inhibitor, DB67, with other antitumor agents.
3. Study the pathway of BPR0Y007-induced apoptosis.
4. Study on the regulation of DNA repair enzyme, MGMT, in human cancer cells.
5. Study on the development of novel microtubule inhibitors.
6. Molecular mechanisms of BPR0L075-resistancy in KB derivative cancer cells.
7. Chemical synthesis, structural bioinformatics and cancer pharmacology － Studies of novel molecular targets for tumor invasion and metastasis.
8. Discovery and development of novel targeted therapeutic agents (histone deacetylase inhibitors, mTOR inhibitors, HSP90 inhibitors, cathepsin S inhibitors, etc.)
9. Translational research of hepatocellular carcinoma: Exploring molecular targets and targeted therapy.
10. Cancer nanotechnology toward clinical applications: smart targeting nanocapsule for simultaneous multi-level genetic/drug manipulation and diagnostic imaging of malignant diseases.
11. Establishment of “Translational Center for Glandular Malignancies (TCGM)”: Focusing on breast, prostate and cholangiocarcinoma.
12. The role of microRNAs in retinoid acid-related pathway during oral carcinogenesis.
13. Preclinical anticancer drug development of a novel compound targeting on alpha-tubulin acetyltransferase.
14. Investigation of the novel role of cathepsin S in the regulation of EGFR signaling: providing a potential basis to improve anti-tumor efficacy of TKI.

Award

1. Outstanding Poster award, The 6^th Annual Taiwan Joint Cancer Conference, 2001
2. Outstanding Poster award, The 8^th Annual Taiwan Joint Cancer Conference, 2003
3. Outstanding Poster award, The 9^th Annual Taiwan Joint Cancer Conference, 2004
4. 徐千田防癌研究基金癌症傑出研究獎 (基礎組), 2005
5. Outstanding Poster Award, The 10^th Annual Taiwan Joint Cancer Conference, 2005
6. Outstanding Poster Award, The 11^th Annual Taiwan Joint Cancer Conference, 2006
7. Outstanding Poster Award, The 12^nd Annual Taiwan Joint Cancer Conference, 2007
8. Outstanding Poster Award, The 13^rd Annual Taiwan Joint Cancer Conference, 2008
9. Outstanding Poster Award, The 15^th Annual Taiwan Joint Cancer Conference, 2010
10. 經濟部國家發明創新獎, 2010
11. Outstanding Poster Award, The 16^th Annual Taiwan Joint Cancer Conference, 2010
12. 第九屆奈米科技菁英獎, 2013
13. 國家新創獎,2023

Publications 2021-2025

Research Articles

1. Chen YL, Yen YC, Jang CW, Wang SH, Huang HT, Chen CH, Hsiao JR, Chang JY and Chen YW. Ephrin A4‑ephrin receptor A10 signaling promotes cell migration and spheroid formation by upregulating NANOG expression in oral squamous cell carcinoma cells. Sci Rep 11:664, 2021
2. Chen SJ, Chen LH, Yeh YM, Lin CCK, Lin PC, Huang HW, Shen MR, Lin BW, Lee JC, Lee YF, Chiang HC and Chang JY*. Targeting lysosomal cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy. Theranostics, 11(10): 4672-4687, 2021
3. Tsai HJ, Hsiah HS, Chang JY, Su WC, Chiang NJ and Chen LT. Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors. Sci Rep Mar 1; 11(1): 4834, 2021
4. Shiah, HS, Chiang NJ, Lin CC, Yen CJ, Tsai HJ, Wu SY, Su WC, Chang KY, Wang CC, Chang JY, Chen LT. Phase I dose escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors. The Oncologist, 26: e567-e579, 2021
5. Chen SH, Hsiao SY, Chang KY and Chang JY*. New Insights into Oral Squamous Cell Carcinoma: From Clinical Aspects to Molecular Tumorigenesis. Int. J. Mol. Sci. 22:2252, 2021
6. Tang CH, Hsiao JR, Jiang SS, Chang JY, Chen PY, Liu KJ, Fang HL, Lin LM, Chen HH, Huang YW, Chen YT, Tsai FY, Lin SF, Chuang YJ and Kuo CC. c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation. Theranostics, Mar 11; 11(11): 5232-5247, 2021
7. Huang CC, Su, YC, Chang CC, Lee WT, Qu CY, Wu, YH, WU SY, Lan YH, Huang TS, Chen KC, Hsueh WT, Tsan ST, Yen CJ, Chang JY, Tsan ML, Lin CL, Weng YC, Yang HC, Chen YS, Hsiao JR and Chang JS. Investigating the association between serum human papillomavirus type 16 E7 antibodies and risk of head and neck cancer. Cancer Medicine 10: 4075-4086,2021
8. Hsu, HY; Yang, CW; Lee, YZ; Lin, YL; Chang, SY; Yang, RB; Liang, JJ; Chao, TL; Liao, CC; Kao, HC; Wu, SH; Chang, JY; Sytwu, HK; Chen, CT; Lee, SJ.  Remdesivir and cyclosporine synergistically inhibit the human coronaviruses OC43 and SARS-CoV-2. Frontiers in Pharmacology. 2021 Aug 13; 12: Article number 706901.
9. Shiah SG*, Chou, ST, Chang JY * MicroRNAs: Their Role in Metabolism, Tumor Microenvironment, and Therapeutic Implications in Head and Neck Squamous Cell Carcinoma. Cancers, 13, 5604, 2021 (invited review).
10. Liu YH, Chen YL, Lai TY, Ko YC, Chou YF, Chen PR, Hsiao JR, Chang JY, Shiah SG, Lee JW, Yang JL, Lin SF. Identification of Prognostic Biomarkers Originating from the Tumor Stroma of Betel Quid-Associated Oral Cancer Tissues. Front. Oncol. 16;11: 769665, 2021
11. Tang YC, Chang HH, Chen HH, Yao JY, Chen YT, Chuang YJ, Chang JY, Kuo CC. A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells. Journal of Food and Drug Analysis 29:638-652, 2021
12. Vidhya Tangeda, Lo YK, Harisanka APB, Chou HY, Luo CL, Kao YH*, Lee AYL* and Chang JY*. Lon upregulation contributes to cisplatin resistance by triggering NCLX-mediated mitochondrial Ca²⁺ release.in cancer cells. Cell Death and Disease.13: 241, 2022
13. Chen YF, Wu CH, Chen LH, Lee HW, Lee JC, Yeh TK, Chang JY* ,MC Chou,  Wu HL, Lai YP, Song JS, Yeh KC, Chen CT, Lee CJ, Shia KS,^,* and Shen MR^,*Discovery of potential neuroprotective agents against paclitaxel-induced peripheral neuropathy. J Med Chem. 65: 4767-4782, 2022
14. Lee YZ, Hsu HY, Yang CW, Lin YL, Chang SY, Yang RB, Liang JJ, Chao TL,  Liao CC, Kao HC, Chang JY, Sytwu HK, Chen CT, Lee SJ*.The synergistic inhibition of coronavirus replication and induced cytokine production by ciclesonide and the tylophorine-based compound dbq33b. Pharmaceutics, 15(2): 342, 2023
15. Hsiao SY; Weng SM, Hsiao JR, Wu YY, Wu JE, Tung CH, Shen WL, Sun SF,  Huang WT, Lin CY, Chen SH, Hong TM, Chen YL*, Chang JY*.MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transition. Journal of Experimental & Clinical Cancer Research, 42:40, 2023
16. Chang CI , Hsieh CC, Wein YS , Kuo CC , Chang CY , Lung J , Cherng JY , Chu PC, Chang JY,* and Kuo YH*. Synthesis and structure-activity relationship of salvinal derivatives as potent microtubule inhibitors. Int. J. Mol. Sci. 24, 6386, 2023
17. Tang, YC, Chuang, YJ, Chang, HH, Juang, SH, Yen, GC, Chang, JY and Kuo, CC. How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy. Journal of Food and Drug Analysis. 31, 3 (2) 387-407, 2023
18. Chih-Peng Lin , Shu-Hui Wu , Tzu-Yin Lin, Chia-Hui Chu , Leu-Wei Lo , Ching-Chuan Kuo , Jang-Yang Chang, Szu-Chun Hsu , Bor-Sheng Ko , Ming Yao , Jong-Kai Hsiao , Shih-Wei Wang , Dong-Ming Huang. Lysosomal-targeted doxorubicin delivery using RBC-derived vesicles to overcome drug-resistant cancer through mitochondrial-dependent cell death. Pharmacological Research. (2023)
19. Hao‑Wei Lee, Szu‑Jung Chen, Kuen‑Jer Tsai, Kuei‑Sen Hsu, Yi‑Fan Chen, Chih‑Hua Chang, Hsiao‑Han Lin, Wen‑Yun Hsueh, Hsing‑Pang Hsieh, Yueh‑Feng Lee, Huai‑Chueh Chiang and Jang‑Yang Chang. Targeting cathepsin S promotes activation of OLF1‑BDNF/TrkB axis to enhance cognitive function. Journal of Biomedical Sciense.(2024)